Drug Approval | December 31, 2022
USFDA grants appeal for Ardelyx's XPHOZAH
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Cipla and Ethris partner for the development of mRNA-based therapies
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Miravo to remain a Canadian controlled and operated company following closing of the transaction
The scheme is subject to statutory and regulatory approvals as may be necessary.
Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients
Subscribe To Our Newsletter & Stay Updated
